DENTSPLY SIRONA INC (XRAY) Stock Fundamental Analysis
NASDAQ:XRAY - Nasdaq - US24906P1093 - Common Stock - Currency: USD
Overall XRAY gets a fundamental rating of 4 out of 10. We evaluated XRAY against 191 industry peers in the Health Care Equipment & Supplies industry. XRAY has a medium profitability rating, but doesn't score so well on its financial health evaluation. XRAY has a bad growth rate and is valued cheaply. XRAY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year XRAY was profitable.
In the past year XRAY had a positive cash flow from operations.
In multiple years XRAY reported negative net income over the last 5 years.
In the past 5 years XRAY always reported a positive cash flow from operatings.
1.2 Ratios
XRAY has a better Return On Assets (-6.23%) than 63.68% of its industry peers.
With a decent Return On Equity value of -16.58%, XRAY is doing good in the industry, outperforming 63.16% of the companies in the same industry.
XRAY's Return On Invested Capital of 4.09% is fine compared to the rest of the industry. XRAY outperforms 75.79% of its industry peers.
XRAY had an Average Return On Invested Capital over the past 3 years of 4.86%. This is below the industry average of 8.08%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.23% | ||
| ROE | -16.58% | ||
| ROIC | 4.09% |
ROA(3y)-3.26%
ROA(5y)-1.52%
ROE(3y)-6.9%
ROE(5y)-3.43%
ROIC(3y)4.86%
ROIC(5y)4.47%
1.3 Margins
XRAY has a better Operating Margin (6.74%) than 73.68% of its industry peers.
In the last couple of years the Operating Margin of XRAY has declined.
The Gross Margin of XRAY (52.18%) is comparable to the rest of the industry.
XRAY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.74% | ||
| PM (TTM) | N/A | ||
| GM | 52.18% |
OM growth 3Y-3.46%
OM growth 5Y-3.12%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.16%
GM growth 5Y0.32%
2. Health
2.1 Basic Checks
XRAY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
XRAY has less shares outstanding than it did 1 year ago.
XRAY has less shares outstanding than it did 5 years ago.
The debt/assets ratio for XRAY is higher compared to a year ago.
2.2 Solvency
XRAY has an Altman-Z score of 1.27. This is a bad value and indicates that XRAY is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of XRAY (1.27) is comparable to the rest of the industry.
XRAY has a debt to FCF ratio of 6.07. This is a slightly negative value and a sign of low solvency as XRAY would need 6.07 years to pay back of all of its debts.
The Debt to FCF ratio of XRAY (6.07) is better than 76.32% of its industry peers.
XRAY has a Debt/Equity ratio of 0.72. This is a neutral value indicating XRAY is somewhat dependend on debt financing.
XRAY has a Debt to Equity ratio of 0.72. This is in the lower half of the industry: XRAY underperforms 70.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.72 | ||
| Debt/FCF | 6.07 | ||
| Altman-Z | 1.27 |
ROIC/WACC0.5
WACC8.22%
2.3 Liquidity
XRAY has a Current Ratio of 1.25. This is a normal value and indicates that XRAY is financially healthy and should not expect problems in meeting its short term obligations.
XRAY has a Current ratio of 1.25. This is amonst the worse of the industry: XRAY underperforms 82.63% of its industry peers.
A Quick Ratio of 0.84 indicates that XRAY may have some problems paying its short term obligations.
XRAY has a worse Quick ratio (0.84) than 85.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.25 | ||
| Quick Ratio | 0.84 |
3. Growth
3.1 Past
The earnings per share for XRAY have decreased by 0.00% in the last year.
The Earnings Per Share has been decreasing by -1.86% on average over the past years.
XRAY shows a decrease in Revenue. In the last year, the revenue decreased by -0.91%.
XRAY shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.11% yearly.
EPS 1Y (TTM)0%
EPS 3Y0.74%
EPS 5Y-1.86%
EPS Q2Q%2.04%
Revenue 1Y (TTM)-0.91%
Revenue growth 3Y5.9%
Revenue growth 5Y-0.11%
Sales Q2Q%0.42%
3.2 Future
XRAY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.82% yearly.
Based on estimates for the next years, XRAY will show a small growth in Revenue. The Revenue will grow by 1.81% on average per year.
EPS Next Y2.38%
EPS Next 2Y3.68%
EPS Next 3Y7.24%
EPS Next 5Y12.82%
Revenue Next Year-2.9%
Revenue Next 2Y-2.39%
Revenue Next 3Y-0.61%
Revenue Next 5Y1.81%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 10.51, the valuation of XRAY can be described as very reasonable.
97.37% of the companies in the same industry are more expensive than XRAY, based on the Price/Earnings ratio.
XRAY's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.64.
XRAY is valuated reasonably with a Price/Forward Earnings ratio of 9.88.
XRAY's Price/Forward Earnings ratio is rather cheap when compared to the industry. XRAY is cheaper than 96.84% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 24.51. XRAY is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.51 | ||
| Fwd PE | 9.88 |
4.2 Price Multiples
XRAY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. XRAY is cheaper than 95.79% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of XRAY indicates a rather cheap valuation: XRAY is cheaper than 97.37% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.59 | ||
| EV/EBITDA | 9.47 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)4.41
PEG (5Y)N/A
EPS Next 2Y3.68%
EPS Next 3Y7.24%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 3.47%, XRAY has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 1.64, XRAY pays a better dividend. On top of this XRAY pays more dividend than 99.47% of the companies listed in the same industry.
XRAY's Dividend Yield is rather good when compared to the S&P500 average which is at 2.28.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.47% |
5.2 History
The dividend of XRAY is nicely growing with an annual growth rate of 9.48%!
XRAY has been paying a dividend for at least 10 years, so it has a reliable track record.
XRAY has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)9.48%
Div Incr Years5
Div Non Decr Years29
5.3 Sustainability
XRAY has negative earnings and hence a negative payout ratio. The dividend may be in danger.
XRAY's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP-30.27%
EPS Next 2Y3.68%
EPS Next 3Y7.24%
DENTSPLY SIRONA INC
NASDAQ:XRAY (1/23/2025, 8:34:09 PM)
After market: 19.44 0 (0%)19.44
+0.08 (+0.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners108.57%
Inst Owner Change0.09%
Ins Owners0.25%
Ins Owner Change-0.13%
Market Cap3.86B
Analysts75.45
Price Target23.62 (21.5%)
Short Float %4.97%
Short Ratio2.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.47% |
Yearly Dividend0.55
Dividend Growth(5Y)9.48%
DP-30.27%
Div Incr Years5
Div Non Decr Years29
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.64%
Min EPS beat(2)-3.31%
Max EPS beat(2)4.59%
EPS beat(4)1
Avg EPS beat(4)-0.19%
Min EPS beat(4)-3.31%
Max EPS beat(4)4.59%
EPS beat(8)4
Avg EPS beat(8)8.47%
EPS beat(12)5
Avg EPS beat(12)3.71%
EPS beat(16)9
Avg EPS beat(16)7.06%
Revenue beat(2)0
Avg Revenue beat(2)-1.89%
Min Revenue beat(2)-3.05%
Max Revenue beat(2)-0.72%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-3.59%
Max Revenue beat(4)1.57%
Revenue beat(8)4
Avg Revenue beat(8)-0.64%
Revenue beat(12)4
Avg Revenue beat(12)-2.22%
Revenue beat(16)7
Avg Revenue beat(16)-0.76%
PT rev (1m)-5.17%
PT rev (3m)-27.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-25.21%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.28%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-1.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.51 | ||
| Fwd PE | 9.88 | ||
| P/S | 0.99 | ||
| P/FCF | 10.59 | ||
| P/OCF | 7.24 | ||
| P/B | 1.55 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.47 |
EPS(TTM)1.85
EY9.52%
EPS(NY)1.97
Fwd EY10.12%
FCF(TTM)1.84
FCFY9.45%
OCF(TTM)2.69
OCFY13.82%
SpS19.62
BVpS12.53
TBVpS-4.95
PEG (NY)4.41
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.23% | ||
| ROE | -16.58% | ||
| ROCE | 5.17% | ||
| ROIC | 4.09% | ||
| ROICexc | 4.34% | ||
| ROICexgc | 15.82% | ||
| OM | 6.74% | ||
| PM (TTM) | N/A | ||
| GM | 52.18% | ||
| FCFM | 9.36% |
ROA(3y)-3.26%
ROA(5y)-1.52%
ROE(3y)-6.9%
ROE(5y)-3.43%
ROIC(3y)4.86%
ROIC(5y)4.47%
ROICexc(3y)5.12%
ROICexc(5y)4.71%
ROICexgc(3y)23.93%
ROICexgc(5y)23.2%
ROCE(3y)6.16%
ROCE(5y)5.66%
ROICexcg growth 3Y-8.57%
ROICexcg growth 5Y-2.64%
ROICexc growth 3Y12.82%
ROICexc growth 5Y2.18%
OM growth 3Y-3.46%
OM growth 5Y-3.12%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.16%
GM growth 5Y0.32%
F-Score4
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.72 | ||
| Debt/FCF | 6.07 | ||
| Debt/EBITDA | 2.95 | ||
| Cap/Depr | 48.84% | ||
| Cap/Sales | 4.33% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 87.68% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.25 | ||
| Quick Ratio | 0.84 | ||
| Altman-Z | 1.27 |
F-Score4
WACC8.22%
ROIC/WACC0.5
Cap/Depr(3y)43.3%
Cap/Depr(5y)38.81%
Cap/Sales(3y)3.64%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y0.74%
EPS 5Y-1.86%
EPS Q2Q%2.04%
EPS Next Y2.38%
EPS Next 2Y3.68%
EPS Next 3Y7.24%
EPS Next 5Y12.82%
Revenue 1Y (TTM)-0.91%
Revenue growth 3Y5.9%
Revenue growth 5Y-0.11%
Sales Q2Q%0.42%
Revenue Next Year-2.9%
Revenue Next 2Y-2.39%
Revenue Next 3Y-0.61%
Revenue Next 5Y1.81%
EBIT growth 1Y-10.85%
EBIT growth 3Y2.24%
EBIT growth 5Y-3.22%
EBIT Next Year21.34%
EBIT Next 3Y10.45%
EBIT Next 5Y10.15%
FCF growth 1Y-16.86%
FCF growth 3Y-25.97%
FCF growth 5Y-6.07%
OCF growth 1Y-10.55%
OCF growth 3Y-16.56%
OCF growth 5Y-5.48%